Trial · NCT02220894
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥50%. | Months | MEDIAN |
| PRIMARY | Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%. | Months | MEDIAN |
| PRIMARY | Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥1%. | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥50%. | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%. | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥1%. | Months | MEDIAN |
| SECONDARY | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥50%. | Percentage of participants | NUMBER |
| SECONDARY | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%. | Percentage of participants | NUMBER |
| SECONDARY | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Up to approximately 44 months | The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥1%. | Percentage of participants | NUMBER |
| SECONDARY | Number of Participants Who Experienced At Least One Adverse Event (AE) | Up to approximately 38 months | The analysis population consisted of all participants who received ≥1 dose of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | Up to approximately 35 months | The analysis population consisted of all participants who received ≥1 dose of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02220894/outcomes